New treatments for pulmonary arterial hypertension using targeted medications
Systemically restricted 5-HT2B antagonists for pulmonary arterial hypertension
['FUNDING_R01'] · VANDERBILT UNIVERSITY · NIH-11017857
This study is working on new medications for people with pulmonary arterial hypertension (PAH) that aim to lower lung blood pressure without causing unwanted side effects like mood changes, so patients can have better treatment options.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-11017857 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new medications to treat pulmonary arterial hypertension (PAH), a serious condition that causes high blood pressure in the lungs. The approach involves creating selective antagonists for the serotonin 2B receptor that do not enter the brain, thereby reducing potential side effects like depression and aggression. The researchers will conduct safety and efficacy tests in preclinical models to ensure these new treatments are safe and effective before moving to clinical trials. This work aims to provide a much-needed therapeutic option for patients suffering from PAH.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who are seeking new treatment options.
Not a fit: Patients with other forms of pulmonary hypertension or those who do not have a diagnosis of pulmonary arterial hypertension may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promise in targeting serotonin receptors for PAH treatment, but this specific approach using systemically restricted antagonists is novel.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MERRYMAN, WILLIAM D — VANDERBILT UNIVERSITY
- Study coordinator: MERRYMAN, WILLIAM D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.